CIK: 0001121404
Total reported value
$336.0M
Reporting period: 2026-03-31 · Number of holdings: 9
Sanofi disclosed 9 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $336.0M and a quarterly turnover rate of 24.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "S"
Sanofi's disclosed holdings carry a Herfindahl concentration index of 0.201 — mathematically equivalent to about 5 equally-sized positions, well below its 9 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.95), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
Recent activity leans toward initiating meaningfully larger new positions than it adds to existing ones (a 8.7 percentage-point tilt) — a pattern consistent with a more contrarian, new-idea-driven approach.
Sector classification currently covers about 17% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim INBX
0.0% -$13.6M
Trim ANAB
0.0% -$9.5M
Add NVAX
0.0% $9.8M
Trim IMRX
0.0% -$3.5M
Add MPLT
0.0% $2.5M
Add ELDN
0.0% $1.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | Stock-Other | 31.44% | +0.20% | — | |
| 2 | INBX | Inhibrx Biosciences INC | Stock-Other | 23.17% | -6.30% | — | |
| 3 | NVAX | Novavax INC | Stock-Healthcare | 16.67% | +1.77% | — | |
| 4 | ANAB | Anaptysbio INC | Stock-Other | 9.04% | -3.80% | — | |
| 5 | AGMB | Agomab Therapeutics NV | Stock-Other | 8.69% | +8.69% | NEW | |
| 6 | MPLT | Maplight Therapeutics INC | Stock-Other | 5.52% | +0.36% | — | |
| 7 | IMRX | Immuneering CORP - Class A | Stock-Other | 4.25% | -1.49% | — | |
| 8 | ELDN | Eledon Pharmaceuticals INC | Stock-Other | 0.75% | +0.35% | — | |
| 9 | QTTB | Q32 Bio INC | Stock-Other | 0.47% | +0.21% | — |
Performance for Q3 2026
-1.1%
Performance Last 4 Quarters
+102.8%
Sanofi's most significant position changes for 2026-03-31: New buy: Agomab Therapeutics NV (AGMB).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NVAX | Novavax INC | +1.8% | — | Unchanged |
| 2 | MPLT | Maplight Therapeutics INC | +0.4% | — | Unchanged |
| 3 | ELDN | Eledon Pharmaceuticals INC | +0.4% | — | Unchanged |
| 4 | QTTB | Q32 Bio INC | +0.2% | — | Unchanged |
| 5 | MGTX | MeiraGTx Holdings plc | +0.2% | — | Unchanged |
| 6 | IMRX | Immuneering CORP - Class A | -1.5% | — | Unchanged |
| 7 | ANAB | Anaptysbio INC | -3.8% | — | Unchanged |
| 8 | INBX | Inhibrx Biosciences INC | -6.3% | — | Unchanged |
| 9 | AGMB | Agomab Therapeutics NV | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-07 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-11 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-04 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-07-29 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-06 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001775530
Total reported value
$335.8M
98 stks
2025-12-31
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001735201
Total reported value
$336.2M
97 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001054257
Total reported value
$335.6M
640 stks
2026-06-30
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000200406
Total reported value
$652.4M
16 stks
2026-03-31
1 of the top 5 holdings overlap, including MeiraGTx Holdings plc
CIK 0001325083
Total reported value
$180.2M
37 stks
2026-03-31
1 of the top 5 holdings overlap, including MeiraGTx Holdings plc
CIK 0001383838
Total reported value
$521.2M
11 stks
2026-03-31
1 of the top 5 holdings overlap, including Novavax INC